AngioDynamics (ANGO)
(Real Time Quote from BATS)
$7.48 USD
-0.10 (-1.32%)
Updated Sep 25, 2024 11:12 AM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Company Summary
Headquartered in Latham, NY, AngioDynamics Inc. designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. The company’s devices are generally used in minimally invasive, image-guided procedures.
AngioDynamics’ products offerings were through three Global Business Units (GBUs), namely Oncology/Surgery, Endovascular Therapies (formerly Vascular Interventions and Therapies) and Vascular Access. However, since the first quarter of fiscal 2023, the company began to manage its operations through two segments, Med Tech and Med Device.
On a pro forma basis, Med Tech (comprising ...
Company Summary
Headquartered in Latham, NY, AngioDynamics Inc. designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. The company’s devices are generally used in minimally invasive, image-guided procedures.
AngioDynamics’ products offerings were through three Global Business Units (GBUs), namely Oncology/Surgery, Endovascular Therapies (formerly Vascular Interventions and Therapies) and Vascular Access. However, since the first quarter of fiscal 2023, the company began to manage its operations through two segments, Med Tech and Med Device.
On a pro forma basis, Med Tech (comprising Auryon, the Thrombectomy platform and NanoKnife) revenues were $105.9 million at the end of fiscal 2024 (39.1% of FY24 total revenues, up 10.1% from FY23).
Med Device (comprising Core, Dialysis, Ports and Microwave products, Vascular Access and Oncology products) revenues were $164.8 million at the end of fiscal 2024 (60.9%, up 2.4%).
AngioDynamics also represents its revenues via geographical segmentation, namely, United States and International.
On a pro forma basis, net sales in the United States were $228.4 million at the end of fiscal 2024 (82.7% of FY24 total revenues, up 3.8% from FY23). Net sales in the International market were $42.3 million at the end of fiscal 2024 (17.3%, up 14%).
In April 2024, AngioDynamics announced that it has entered into a settlement agreement with Becton, Dickinson and Company to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD. AngioDynamics is likely to benefit from the settlement of this prolonged legal dispute to a successful resolution as it will lower the company’s ongoing legal expenses and terminate more than 10-year distraction.
In February 2024, AngioDynamics optimized its product portfolio as it sold its PICC and Midline business to Spectrum Vascular. Additionally, the company also discontinued sales of Uniblate and Starburst Radio Frequency products along with Syntrax support catheter as these products were not core to its growth strategy.
General Information
AngioDynamics, Inc
14 PLAZA DRIVE
LATHAM, NY 12110
Phone: 518-795-1400
Fax: 518-795-1401
Web: http://www.angiodynamics.com
Email: mpolyviou@evcgroup.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | May |
Last Reported Quarter | 8/31/2024 |
Earnings Date | 10/3/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.15 |
Current Year EPS Consensus Estimate | -0.41 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 10/3/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 7.58 |
52 Week High | 8.25 |
52 Week Low | 5.26 |
Beta | 0.65 |
20 Day Moving Average | 270,825.81 |
Target Price Consensus | 13.33 |
4 Week | -0.66 |
12 Week | 31.12 |
YTD | -4.34 |
4 Week | -2.43 |
12 Week | 25.54 |
YTD | -20.21 |
Shares Outstanding (millions) | 40.28 |
Market Capitalization (millions) | 302.07 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -400.00% |
vs. Previous Quarter | 62.50% |
vs. Previous Year | -22.06% |
vs. Previous Quarter | -5.59% |
Price/Book | 1.48 |
Price/Cash Flow | 1.77 |
Price / Sales | 1.00 |
8/31/24 | Pending Next EPS Report |
5/31/24 | -4.91 |
2/29/24 | -3.48 |
8/31/24 | Pending Next EPS Report |
5/31/24 | -3.76 |
2/29/24 | -2.68 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 2.12 |
2/29/24 | 2.29 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 1.46 |
2/29/24 | 1.62 |
8/31/24 | Pending Next EPS Report |
5/31/24 | -5.07 |
2/29/24 | -3.83 |
8/31/24 | Pending Next EPS Report |
5/31/24 | -61.55 |
2/29/24 | -60.21 |
8/31/24 | Pending Next EPS Report |
5/31/24 | -63.06 |
2/29/24 | -61.53 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 5.13 |
2/29/24 | 5.49 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 2.46 |
2/29/24 | 2.72 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 0.00 |
2/29/24 | 0.00 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 0.00 |
2/29/24 | 0.00 |